StockTipsArenaBeta

BUY Sun Pharmaceutical Industries Ltd. — BOB Capital Markets

BUYSun Pharmaceutical Industries Ltd.

byBOB Capital MarketsHorizon: NA (inferred 1 year)23 May 2025via Institutional / Brokerage Research

Entry₹1,683.6Inferred
Target₹1,993
Total upside +18.38% (call closed)
Stop lossNot given
At expiry₹1,844.622 May 2026, 3:30 pm
Expired+9.56%
Follow BOB Capital Markets for new calls(63% target hit, 356 closed calls)Get alertsWatch SUNPHARMA for new buy/sell callsGet alertsSee 14 active Long-term calls on SUNPHARMA

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 1:43 am IST
1 supporting3 neutral0 opposing
Supports the BUY call (1)

3 other SEBI-registered advisors have active long-term BUY calls on this stock

Advisor consensus · same horizon·28 Apr · 3w ago

Neutral / worth noting (3)

Sun Pharmaceutical Industries Limited has submitted to the Exchange, the Audited Financial Results for the quarter and year ended 31 March 2026.

NSE · Outcome of Board Meeting·22 May · today

(opens in new tab)

CRISIL and ICRA have reaffirmed Sun Pharma's long-term bank facilities ratings at 'AAA' and short-term ratings at 'A1+'. CRISIL has placed the long-term rating on 'Rating Watch with Developing Implica

BSE · Company Update·7 May · 2w ago

(opens in new tab)

Sun Pharmaceutical Industries Limited will hold an investor call to discuss the acquisition of Organon & Co.

NSE · Press Release·27 Apr · 4w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.